maximizing treatment benefits in nsclc
Published 7 years ago • 31 plays • Length 1:40Download video MP4
Download video MP3
Similar videos
-
3:53
how to maximize clinical benefits for patients with alk-positive non-small cell lung cancer
-
1:41
recent developments in the treatment of nsclc
-
4:37
treatment options for brain metastases in nsclc
-
1:54
balancing the benefits and costs of immunotherapy in the treatment of lung cancer
-
5:59
targeted therapy in consolidation setting for lung cancer
-
1:56
recent approvals in the nsclc treatment landscape
-
3:28
the future of nsclc treatment
-
1:06
optimizing precision medicine in nsclc
-
1:14
treatment sequecing strategies in advanced nsclc
-
6:55
the prognostic value of ctdna in nsclc treated with neoadjuvant chemoimmunotherapy
-
2:22
moving immunotherapy to earlier lines in nsclc
-
2:31
differences in treating lung cancer with adjuvant and neoadjuvant immunotherapy
-
3:34
alk-positive nsclc: the role of treatment selection and sequencing
-
1:30
immunotherapy in second-line treatment of non-small cell lung cancer
-
0:48
chemotherapy-free immunotherapy-based treatment approaches for nsclc
-
43:35
maximizing the impact of egfr-targeted therapy in resectable nsclc
-
4:08
targeted therapies in lung cancer
-
4:13
next steps in nsclc: checkpoint inhibitors plus cellular therapy
-
4:38
targeted therapy in nsclc at asco 2020